Zimmer Biomet Holdings, Inc. with ticker code (ZBH) have now 23 analysts in total covering the stock. The consensus rating is pointing to ‘hold’. The target price High/Low ranges between $160.00 and $109.00 and has a mean share price target at $136.04. (at the time of writing). Now with the previous closing price of $124.40 this is indicating there is a potential upside of 9.4%. The 50 day MA is $121.83 while the 200 day moving average is $123.47. The company has a market cap of 26.06B. The stock price is currently at: $124.71 USD
The potential market cap would be $28,500,619,010 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 25.56, revenue per share of $35.43 and a 4.35% return on assets.
Zimmer Biomet Holdings, Inc. is a global medical technology company. Its segments include Americas, EMEA, and Asia Pacific. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic (CMFT) products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its other product category primarily includes its robotic, surgical and bone cement products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System. Its S.E.T. product category includes sports medicine, biologics, foot and others.
